05B4 Weiss, Mark - Thomas Jefferson University - Thomas Jefferson University
Dr. Weiss

Mark Weiss, MD

Contact Dr. Weiss

925 Chestnut Street
Suite 420A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  2. Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
  3. Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit
  4. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation
  5. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia
  6. Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial
  7. Treatment of adult ALL: More questions than answers
  8. Treatment of adult ALL: more questions than answers.
  9. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  10. The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia
  11. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
  12. Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic 0E31 lymphocytic leukemia
  13. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
  14. Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
  15. Pentostatin in chronic lymphocytic leukemia
  16. Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion
  17. Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections
  18. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
  19. Richter's syndrome: Factors to predict response and survival
  20. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia